MYC and cancer: More importantly, a potent and selective inhibitor for BRD7 was reported recently (Clark et al., 2015), which provides a promising therapeutic option for BRD7-driven cancers, revealing that targeting the BRD7/c-Myc axis could be an attractive approach for the treatment of c-Myc-driven cancers.